Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025

Reuters

Aug 29

Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025

Sinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2563021321"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563021321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563021321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563021321","market":"nz","top_or_hot":-1,"title":"Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> has released its 2025 interim report highlighting the financial performance of its subsidiary, <a href=\"https://laohu8.com/S/000028\">China National Accord Medicines</a> Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-29 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> has released its 2025 interim report highlighting the financial performance of its subsidiary, <a href=\"https://laohu8.com/S/000028\">China National Accord Medicines</a> Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000028","symbol_name":"国药一致","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL8P1dQ2:1","article_id":"2563021321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563021321","pubTimestamp":1756475687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. . The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"000028":"国药一致","01099":"国药控股"},"translate_title":"国药一致报告2025年上半年收入和利润下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000028":0.9,"01099":0.9},"content_text":"Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    \n\nSinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}